Apimeds Pharmaceuticals US, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2023 | $390.2K | $422.1K | $410.5K |
| FY2024 | $1.4M | $13.1K | $3.5K |
| FY2025 | $10.8M | $164.2M | $1.6M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2023 | $390.2K | $422.1K | $410.5K |
| FY2024 | $1.4M | $13.1K | $3.5K |
| FY2025 | $10.8M | $164.2M | $1.6M |